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Angiotensin II (All) has been implicated as an important
factor in the pathophysiology of heart diseases. Following
the recent identification of two subtypes of the AH receptor
in cardiac tissue of animals, we investigated the possible
occurrence of these, or similar, subtypes in human atrial
tissue. In right-atrial tissue from patients undergoing heart
surgery, we determined the All-receptor profile in receptor
binding studies, using [l25I]-angiotensin as radioligand and
All as well as two compounds selective for the receptor
subtypes to identify and quantify All-receptor subpopula-
tions. In 35 patients (23 requiring coronary bypasses, 10
valvular surgery and two combined coronary and valvular
surgery), the left-ventricular ejection fraction was deter-
mined in the preoperative phase, and right- and left-atrial
pressure during surgery. In membranes of human right
atria, All receptors are present in high density (median:
Bmax=294 fmol. mg ~ ' protein, range: 111-2073) and two
different subtypes can be distinguished. Type-1 receptors
(AT,) accounted for 33 ± 10% of the population whereas
type-2 receptors (ATj) made up 67 ± 10% of the popu-
lation. There was no correlation between any of the
measured cardiac functions and total All-receptor density
or receptor affinity. However, the percentage of AT, recep-
tors was higher in the atria of patients with normal right-
atrial pressure; left-ventricular ejection fraction was
positively and right-atrial pressure inversely correlated with
the percentage of AT, receptors (r=0-740 and -0-901,
respectively; P<0-001, for both). Moreover, the percentage
of AT2 receptors was directly correlated with the levels of
left-atrial pressure (r=0-853; P<0001). It is concluded that
the ratio of AT, to AT2 receptors correlates well with
right-atrial pressure and left-ventricular function. This is a
first indication of a possible involvement of All-receptor
subtypes in the pathophysiology of cardiac dysfunctions.
(Eur Heart J 1996; 17: 1112-1120)
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Introduction
Angiotensin II (All) is the principal effector peptide of
the renin-angiotensin system, which is the major regulat-
ory mechanism for electrolyte balance and blood pres-
sure. There is also increasing evidence of the existence of
an intrinsic renin-angiotensin system in the heart: find-
ings made mainly in animals show the presence in myo-
cardial tissue of mRNAs coding for angjotensinogen and
renin'1"41, and of renin, angiotensin-converting enzyme,
and All, as well as its receptor15"131.
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The physiological and pathophysiological roles
of this All-generating pathway and the circulating All
in the heart have not yet been fully elucidated. However,
they may include inotropic and chronotropic activities,
effects on coronary vascular tone, arrhythmogenesis,
and impairment of relaxation, as well as a permissive or
regulatory role in modulating cardiac growth and
development'14"181. There is indirect evidence tending to
implicate the renin-angiotensin system in the initiation
of proto-oncogene expression and cell growth in smooth
muscle and myocardial cells'19"251, and inhibition has
been shown to prevent left ventricular hypertrophy in
rats with pressure overload'26"281 and to promote the
regression of chronic pressure-overload hypertrophy in
man'29"301.
Recently, two distinct subtypes of All receptors
have been discovered'31"341. They can be identified
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Table 1 Patient characteristics
Patient
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
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19
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21
22
23
24
25
26
27
28
29
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Sex
M
M
M
M
F
M
F
M
M
M
M
F
M
M
M
M
M
F
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
Age
67
53
73
60
68
47
33
59
63
56
60
60
65
67
64
43
67
65
58
72
60
58
63
62
49
54
53
66
62
71
58
53
59
41
67
Intervention
C
C,V
C
C
V
V
V
C
c
c
V
V
c
c
c
V
c
V
c
c
c
c
V
c
V
c
c
c
c
c
V
c
c
c
c,v
Medication
B,C,N
N,O
A,C,B,N
C,D,Ao,O
D
C,D,Ao,G
—
C,D,N
B,N,0
B,C,N
A
G,0
C
B,C,N
B,C,N
—
A
D,G,O
B,C,N
C,O
B.C.N
B,C
A,B,C,N,G,T
CD
A,C,D,Ao,G
B,C,N
B,C,N
B,N,C,O
B,C,Ao,N
B,C,N
—
B,C
B,Ao
B,C,Ao,N
D, 0
Systolic BP
(mmHg)
120
120
110
160
120
125
105
110
140
130
125
120
130
120
170
140
160
100
130
165
150
125
110
110
120
130
120
110
110
120
130
110
110
110
Diastolic BP
(mmHg)
70
80
70
80
60
70
70
70
80
70
56
70
70
65
90
—
80
100
80
75
65
90
70
70
70
80
80
70
65
80
80
70
75
80
80
EF
(%)
66
58
49
68
62
34
31
67
64
40
69
34
51
50
79
—
36
41
58
59
50
46
56
33
40
56
64
59
52
36
35
48
44
46
41
C=coronary bypass surgery; V = replacement of valve(s).
A = ACE inhibitor; Ao = anticoagulant; B=/J-adrenergic antagonist; C = calcium antagonist;
D=diuretic; G=glycoside; N = nitrate; T=other cardiotonics; O=others.
BP=blood pressure. EF=ejection fraction.
unequivocally with the aid of the novel agents Losartan
and CGP 42 112 A, which have an inverse affinity for the
subtypes and selectivity factors of more than lOOO13'1.
Losartan is a specific non-peptidic AH antagonist hav-
ing a high affinity for the AT, subtype, to which several
functions, such as vasoconstriction, can be attributed;
the function of the AT2 subtype, which shows the
greatest affinity for CGP 42 112 A remains unclear131"351.
Both subtypes have been demonstrated in rabbit
myocardial tissue1361 and rat myocardium'371.
The potential functional significance of the two
cardiac All-receptor subtypes is unknown. Up to now,
no attempt had been made to differentiate All-receptor
subtypes in human myocardial tissue. This paper
reports, for the first time, the existence and the proper-
ties of two subtypes in human right atria. If All-receptor
subtypes play a role in cardiac function, their abundance
or properties may differ according to the degree of
dysfunction. Studies in rats have indicated changes in
All-receptor subtypes with cardiac hypertrophy using
different models'38'39'. To test this hypothesis, we inves-
tigated the All-receptor subtypes in right-atrial tissue
from patients with varying degrees of cardiac dysfunc-
tion. Our results demonstrate that the relative propor-
tions of the All-receptor subtypes are closely associated
with altered diastolic and systolic properties of the heart.
Methods
Patients and study design
Atrial-tissue specimens (0-6 ± 0-2 g; mean ± SD) were
excised from the right-atrial appendage during cannu-
lation in 35 patients (31 males, four females, aged 60 ± 9
years, weighing 81 ±12 kg and 173 ± 8 cm in height)
undergoing open-heart surgery. The left-ventricular
ejection fraction was derived from the levocardiogram
recorded during preoperative left-heart catheterization
in all but one patient (51 ± 13%, n = 34).
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Prior to surgery, all but three patients had been
receiving medical therapy (Table 1): two patients had
been on monotherapy and the remaining 30 on com-
bined medication with two or more drugs of the follow-
ing categories (calcium-channel blockers in 22; nitrates
in 17, beta-blockers in 18; antiarrhythmic agents in
eight; glycosides in six; diuretics in eight; converting-
enzyme inhibitors in five; antiplatelet drugs in 10; oral
anticoagulants in seven). The antiplatelet agents
were withdrawn 10 days before the operation and the
anticoagulants on the day before surgery.
On the night before surgery, the patients received
flunitrazepam (1 mg) orally and 1 h before induction
of anaesthesia morphine (01 mg. kg"1) with hyoscine
hydrobromide (01 mg . 25 kg" ') intramuscularly.
Anaesthesia was induced with either sodium thiopental
(2-3 mg. kg" ' ) or etomidate (0-2 mg . kg" ' ) plus fen-
tanyl citrate (3-5 ug. kg"1). To maintain anaesthesia,
enfluorane (0-3-10 volume % in an air/oxygen mixture)
and supplementary doses of fentanyl were used. Pan-
curonium bromide (01 mg . kg" ') was given as muscle
relaxant. Ventilation was controlled to maintain the
partial pressure of carbon dioxide between 4-5 and
50 kPa and the inspiratory flow of oxygen was set at
06. Right- (7 ± 4 mmHg) and left-atrial pressures
(8 ± 5 mmHg) were recorded, and the values closest to
the time of excision of right-atrial tissue (maximum
20 min) were taken for analysis. In 23 patients,
coronary-bypass surgery was performed, in 10 patients
replacement of one or two valves (aortic valves in six;
four for aortic stenosis, three for aortic regurgitation:
mitral valves in four; three for mitral regurgitation and
one for mitral stenosis) and two patients received bypass
grafts and aortic valve replacements (both for aortic
stenosis, with additional regurgitation in one). The clini-
cal and biochemical evaluations were performed separ-
ately, and the investigators were blinded for putative
dependent variables. The codes were not broken until
the two sets of data were ready to be collated.
Membrane preparation
Intraoperatively excised right-atrial tissue was immedi-
ately rinsed in ice-cold cardioplegic solution, frozen in
liquid nitrogen and stored at — 80 °C. Atrial membranes
were prepared using a slight modification of a published
procedure'361. In brief, the tissue was thawed on ice
and a homogenate (20% w/v) was prepared in 0-25 M
sucrose, 25 mM Tris pH 7-5, with a Polytron (2 x 30 s)
at setting 6. The homogenate was sedimented at 10 000 g
for 20 min, the pellet discarded and the supernatant
centrifuged at 100 000 g for 30 min. The pellet was
resuspended in 5 ml of 06 M KG and 30 mM histidine
at pH 70 (per g of tissue) and resedimented at 100 000 g
for 30 min. The pellets obtained from the final centri-
fugations were washed three times and resuspended
in 25 mM Tris pH 75 and 10 mM MgCl2 using a
tight-fitting Teflon-pestle homogenizer. AH steps above
were carried out at 0-4 °C. The membrane preparations
were frozen in liquid nitrogen and held in aliquots at
- 80 °C until used. There was no apparent loss of
All-binding activity with time. Protein was assayed by
the method of Bradford1401 using bovine serum albumin
from Sigma as standard.
Binding assay
Equilibrium-binding studies were performed at 25 °C for
50 min in 01 ml Tris pH 7-5 containing MgCl2 (10 mM),
bovine serum albumin (0-2%), membranes (4-9 ± 2-8 ug
protein; mean ± SD), [I25I]-AII (2200 Ci/mmol pur-
chased from Anawa, Wangen, Switzerland; Concen-
trations as stated in the figures), and the peptidase
inhibitors antipain, phosphoramidon, leupeptin, pepsta-
tin, bestatin, amastatin, each at 1 ug . m l " ' (all obtained
from Novabiochem, Laufelfingen, Switzerland), and
bacitracin at lOOug.ml"1. Control experiments
showed that under these conditions equilibrium was
reached and the binding was linearly related to the
amount of protein used. Bound and free ligand were
separated by addition of 4 ml of ice-cold Tris pH 7-5 and
subsequent rapid filtration through Whatman GF/F
filters presoaked in 0 1 % bovine serum albumin. This
was followed by three additional washes with 4 ml of the
same buffer, and radioactivity trapped on the filter was
then measured in a gamma-counter (Pharmacia LKB,
Uppsala, Sweden) at 80% efficiency. Non-specific
binding was determined in the presence of 10 uM un-
labelled All (human sequence; obtained from Bachem,
Bubendorf, Switzerland). Typically, values of total
bound All were about 2000 cpm and non-specific
binding amounted to about 500 cpm.
The proportions of the receptor subtypes were
determined in inhibition experiments performed in trip-
licate, using selective concentrations of CGP 42 112 A
(0-3 uM) and Losartan (3 uM), respectively (Losartan
and CGP 42 112 A were synthesized by Ciba-Geigy).
The integrity of the radioligand before and after incu-
bation was determined by reversed-phase thin-layer
chromatography, as described elsewhere'361. These con-
trols showed that under the incubation conditions used
as much as 84 ± 1% (n = 35) of the radioligand remained
intact.
Data analysis
The binding data were analysed using the LIGAND
curve-fitting program'4'1. The data were obtained from
experiments each performed in duplicate, and the geo-
metric means are given when dose-response curves were
averaged. The means of the percentages of AT! and AT2
receptors calculated from the two determinations using
selective concentrations of CGP 42 112 A and Losartan,
respectively, were averaged. All other data were ana-
lysed with Student's t-test and linear regression. Results
are expressed as mean ± SD, unless otherwise stated.
Differences at /*<0-05 were accepted as statistically
significant.
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Figure 1 Saturation binding of |I25I|-AII to human right-atrial membranes.
Specific ( • ) and non-specific binding (A) as a function of increasing concen-
trations of | IJ-AII is shown. A Scatchard analysis of the data is given in the
inset. The values given are representative of three experiments. The experiment
is an example showing the occurrence in human atrial membranes of ATI
receptors having a high affinity and density.
Results
Identification of All-receptor subtypes in
human atrial membranes
Saturation binding of [125I]-AJI to human right-atrial
membranes is depicted in Fig. 1. The data demonstrate
the presence of specific sites with high affinity for AIL
In the 35 specimens investigated, the median receptor
density was 294 fmol. mg~' protein (range 111-2073).
Half-saturation of the receptors is reached at 1-3 nM
(range 0-6-2-0). To characterize the All receptors in
human atria, we performed separate competition-
binding experiments (n = 35 for All; n = 2 for each
subtype-selective competitor) (Fig. 2). AH displaces the
radioligand monophasically. The Hill coefficient is near
unity. These data indicate the presence of one homo-
geneous class of high-affinity receptors. The highly
selective ligands, CGP 42 112 A and Losartan, possess-
ing an inverse affinity for AH-receptors subtypes, how-
ever, displace the radioligand in a biphasic manner,
unmasking the presence of two distinct binding sites.
These were further characterized in competition-binding
experiments performed in the presence of CGP 42 112 A
and Losartan in concentrations sufficient to block their
high-affinity sites (Fig. 3). These experiments show that
All possesses the same affinity for the two receptor
subtypes. However, Losartan has a 1000 times higher
affinity for the AT, than for the AT2 receptor and,
conversely, CGP 42 112 A has a high affinity for the AT2
receptor and only a very weak affinity for the AT,
receptor. This demonstrates the pharmacological differ-
ence between these two entities. Furthermore, it was
100
o
m
-Log [Competitor] (M)
Figure 2 Competition curves with AH ( • ) , CGP 42 112
A ( • ) and Losartan (A) in human right-atrial membranes.
The experiments were carried out in the presence of
0-5 nM |12SIJ-A1I. The biphasic displacement curves of the
subtype-specific antagonists demonstrate the presence of
AT, and AT2 receptors.
found that they are chemically distinguishable. They are,
for instance, affected differently by the disulphide-
reducing reagent dithiothreitol: the AT, receptor is
inhibited, whereas the binding of the hormone to the
AT2 receptor is stimulated (Fig. 4).
AH receptors and correlation with cardiac
parameters
Figure 5 illustrates the lack of correlation between the
density of total All receptors and the ejection fraction.
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Figure 3 Inhibition of [I25I1-AII binding, by All ( • ) ,
CGP 42 112 A ( • ) and Losartan (A) to AT, and AT2
receptors in human right-atrial membranes, (a) The AT,
receptor was unmasked by blocking AT2 receptors with
CGP 42 112 A (0-3 uM). (b) The AT2 receptor was
unmasked by blockade of AT, receptors using Losartan
(3 uM). The experiments were carried out in the presence
of 0-5 nM [I25I]-AII, and the data given are represen-
tative of two experiments each. The two sets of exper-
iments show the pharmacological profile of the AT,
receptor (binding affinity orden AII>Losartan>CGP
42 112 A) and the AT2 receptor (CGP 42 112
A > A D > Losartan).
200 -
1 10
Dithiothreitol (mM)
100
Figure 4 Effect of various concentrations of dithiothrei-
tol on the binding of 0-5 nM |125I1-AII, to subtypes of Al l
receptors of human atrial tissue. The experiments were
carried out in the presence of 0-3 uM CGP 42 112 A (O)
and 3 uM Losartan ( • ) , respectively, to investigate
the effect of DTT on subtypes 1 and 2 separately (see
Figs 2 and 3). The data given are representative of two
experiments each.
n
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Figure 5 Lack of relation of between density of total All
receptors and ejection fraction.
Moreover, there was no demonstrable association
between alterations in left- or right-atrial pressure and
changes in the density of total All receptors, or their
affinity for the hormone (data not shown).
Both AH-receptor subtypes were detected in the
atria of all 35 patients. Although the mean distribution
comprised 33 ± 10% AT, receptors and 67 ± 10% of the
AT2 type, there was a fairly wide range of interindi-
vidual variation: some patients had almost identical
proportions of the two subtypes, but in extreme cases
the ratio of AT^AT, was up to 7:1. The analysis of the
data revealed a striking association between the propor-
tions of the receptor subtypes and the various cardiac
parameters measured (Fig. 6). It was found that the
proportion of AT, receptors increases significantly with
the left-ventricular ejection fraction (Fig. 6(a)). There
was a highly significant, direct correlation between the
height of the left-atrial pressure and the proportion of
AT2 receptors (Fig. 6(b)). Furthermore, the height of
right-atrial pressure and the percentage of AT2 receptors
were positively correlated (Fig. 6(c)). In summary, these
findings indicate that the proportion of AT, receptors in
right-atrial tissue decreases, and concomitantly the pro-
portion of AT2 receptors increases with the degree of
impairment of the cardiac functions measured.
Analysis of relationships between the absolute
density of the receptors was hampered by the vari-
ation in the total receptor number, mainly caused
by two extreme values with densities exceeding
1000 fmol. mg~ ' of protein (see Fig. 5). Hence, with the
exception of two individuals the patients had a receptor
density with a variation expected in biological samples.
We carefully investigated all characteristics including
medication of two 'outlayers' and found no explanation
for this phenomenon. Re-analysis of the data after
exclusion of these two values revealed significant corre-
lations between the absolute density of AT, receptors
(%AT, x BmaJ and alterations in the various cardiac
functions: the height of the ejection fraction correlates
positively (r=0-44, P<002, n = 32) and the heights of
both left- and right-atrial pressures showed an inverse
correlation (r= -0-45, P<0-02, n = 31) and (r= -0-40,
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Figure 6 Relationship between tbe proportion of receptor subtypes and cardiac par-
ameters. The data show significant correlations between tbe proportions of AH receptor
subtypes and ejection fraction (a), left-atrial pressure (b) as well as right-atrial pressure
(c). In tbe panels depicting tbe fraction of AT2 receptors, the circles indicate tbe values
from patients who underwent coronary-bypass surgery and tbe triangles those from
patients who underwent valvular surgery. The data indicate a decrease in the proportion of
AT, receptors with increasing degree of dysfunction of all cardiac parameters measured
(and a reciprocal situation for tbe AT2 receptors) irrespective of tbe underlying disease
state. For (a), r=O740 and /»<0-001; (b), r= - 0-853 and /><0-001; (c) r= - 0-901 and
P<0-03, n = 33). This indicates that a decrease in AT,
receptor numbers in the right atrium is associated both
with increased right-atrial pressure and with impaired
left systolic and diastolic function. The AT2 receptor
density showed an opposite tendency [ejection fraction:
r= -0-20 (ns); left-atrial pressure: r=0-34, .P=0-06 (ns),
right-atrial pressure: r=0-40, P<003]. This was ex-
pected, since the data on total receptor density and the
parameters of cardiac function showed no correlation.
However, no significant correlation between any
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receptor parameters and the patients' ages or body
weights was demonstrable (data not shown).
In conclusion, these data indicate that the rela-
tive proportions of AT, and AT2 receptors in human
atrial tissue show a good correlation with right-atrial
pressure and left-ventricular functions in these patients.
Discussion
In right-atrial tissues from 35 patients undergoing car-
diac surgery, we have demonstrated the presence of a
dense population of high-affinity All receptors, compris-
ing both AT, and AT2-receptor subtypes, and found the
proportions as well as the absolute density of these two
subtypes to be related to the height of right- and
left-atrial pressures and the left-ventricular ejection frac-
tions. Our findings contrast with the results of previous
studies in human cardiac tissue1'0'42', in which very low
densities of All receptors (Bmax<7 fmol , m g " ' protein)
were detected in normal subjects and patients with
idiopathic or dilated cardiomyopathy: the values quoted
for right-atrial tissue (the highest density recorded) were
more than 40 times less than those determined in our
patients. This discrepancy may have been due to metho-
logical differences, such as dissimilarities in the purity of
the membranes, or possibly to denaturation of the
receptors, since the cardiac tissue had been kept for
several hours in ice-cold cardioplegic solution before
being frozen'101 whereas in the present study fresh,
snap-frozen tissue was used. In addition, we investigated
the receptors in atrial tissue, which in rabbit hearts has
been shown to possess an All receptor density about 10
times higher than that of ventricular tissue151. In very
preliminary experiments this difference has also been
found in human hearts in our laboratory (H. Rogg,
unpublished observations). However, the reported
absence of any clear-cut difference in the density of total
All receptors in normal and failing hearts agrees with
our findings showing a lack of correlation between this
parameter and the various cardiac functions.
This first study of human cardiac All receptors
was carried out prior to the initial report of the existence
of All-receptor subtypes'3'1 and the discovery of their
coexistence in rabbit ventricular tissue1361, and the tissues
investigated were cardiac explants. In our study, we
examined specimens excised during heart surgery. The
possibility that the anaesthetics or the cardiac drugs
administered prior to surgery may have influenced
the results cannot be excluded. Although the tissue
originated from patients on multiple drugs, specimens
exposed to single drugs were too few in number to be
analysed separately. At least no obvious effect of
angiotensin-converting enzyme inhibitors (n = 5 of 35
patients) on the proportions of All receptor subtypes
was detectable (data not shown).
The analysis of the 35 specimens revealed a
direct relation between the proportion of All receptor
subtypes and right- and left-atrial pressures, as well
as left-ventricular ejection fraction. Since these three
parameters were interrelated in the patients studied, the
influence of a single abnormal parameter cannot be
determined separately.
The main outcome of our study is the demon-
stration of the occurrence of the two All-receptor sub-
types in human atrial tissue and their close relations
to various cardiac functions. The properties of the
two atrial subtypes are indistinguishable from those
in other tissues such as uterus, adrenal glands and
vascular smooth-muscle cells'3'1, as well as in rabbit
ventricles'361. The order of affinity of the AT, subtype
(AII>Losartan£>CGP 42 112) clearly differentiates it
from the AT2 subtype (CGP 42 112 A>AIl£>Losartan).
Furthermore, the two subtypes have different suscepti-
bilities to the disulphide-reducing reagent dithiothreitol
in human atria and other tissues'31"34'361: the AT! recep-
tors is inhibited, whereas the binding of the hormone to
the AT2 receptor is stimulated by DTT. This furnishes
additional evidence for the distinct nature of the two
subtypes of All receptors in human atrial tissue.
Atrial tissue was chosen for these investigations
of human cardiac All-receptor subtypes because it can
be obtained fresh and because earlier reports indicated
that atria may be the cardiac tissue with the highest
receptor density, both in animals and in man'5'101. The
demonstrable correlations between different proportions
of the two All-receptor subtypes and right-atrial pres-
sure, and especially left-ventricular systolic and diastolic
function, afford the first indication of the possible
involvement of these entities in a pathophysiological
process. The individuals investigated have the character-
istics of a large proportion of cardiac patients suitable
for heart surgery. The receptor profile of patients with
either valvular disease or coronary artery disease did not
deviate from the correlations (Fig. 6). However, none of
them had other heart disease such as dilated cardiomy-
opathy. Accordingly, our finding cannot be extrapolated
to such conditions. Although at this stage it is obviously
impossible to tell whether these changes are a cause or a
consequence of cardiac dysfunction, it is tempting to
speculate that the cardiac AT, receptor, which is known
to be coupled to a G protein'431, may be down-regulated
with the degree of cardiac dysfunction, in a similar
fashion to the alterations in beta-adrenergic receptors in
these conditions'441. Thus, the effects of AT, receptor,
known to be mediated via phosphoinositol break-
down'341 leading to an elevation of intracellular free
calcium'35', might conceivably result in sluggish calcium
transients and hence reduced contractile force in patients
with altered left-ventricular systolic function as a
consequence of receptor down-regulation.
An increase in angiotensin-converting enzyme
activity and mRNA expression has been reported in rats
with pressure-overload left-ventricular hypertrophy1451.
This indicates that in some forms of cardiac dysfunction
the local renin-angiotensin system may be activated and
linked to cardiac hypertrophy. Moreover, All is thought
to play a permissive or regulatory role in modulating
cardiac growth and development'14"18'. The reported
alteration in the proportion of the All-receptor subtypes
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associated with cardiac dysfunction in this study may
have both theoretical and practical implications. The
possibility cannot be excluded that these alterations may
play an important role in the progression of structural
changes in the myocardium, either linked to ischaemic
heart disease or to chronic pressure overload. Unfortu-
nately, the effector pathway(s) of the AT2 receptors, and
their function is still controversial. Therefore, it would
be premature to speculate on a permissive or restrictive
involvement of AT2 receptors in the regulation of
growth. However, the high density of this subtype
found in the fetus may play a functional role in
development146-471.
The association between both the proportion
and the density of the AT, receptor subtype and cardiac
dysfunction reported in this study may be of direct
therapeutic relevance. The non-peptidic AT,-specific
receptor antagonist Losartan and other compounds of
the same class are in preclinical or clinical development.
Recent initial reports of the effects of Losartan in man
describe a marked elevation of circulating AII[481. In a
recent study comparing the effects of Losartan and an
angiotensin-converting enzyme inhibitor in rats, it was
demonstrated that the latter compound causes no appre-
ciable change in circulating All1491. It is consequently not
admissible to draw inferences regarding the effects of
AT,-selective inhibition from the cardiac effects of
angiotensin-converting enzyme inhibition. Given the
presence of both the AT, and AT2 receptor subtypes on
human cardiac tissue, blockade of the AT, subtype by
treatment with such drugs exposes the AT2 subtype to
elevated All levels, with unpredictable, either desirable
or undesirable, long-term cardiac effects.
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